Clover Biopharmaceuticals, Ltd. (2197.HK)
| Previous close | 0.365 |
| Open | 0.365 |
| Bid | 0.365 x N/A |
| Ask | 0.370 x N/A |
| Day's range | 0.360 - 0.370 |
| 52-week range | 0.300 - 1.810 |
| Volume | |
| Avg. volume | 1,408,331 |
| Market cap | 473.146M |
| Beta (5Y monthly) | 3.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.120 |
| Earnings date | 19 Aug 2024 - 20 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.91 |
PR NewswireClover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive preliminary immunogenicity and safety data in the older adult & elderly cohort from its Phase Ⅰ trial evaluating SCB-1019 – the company's bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate – which is based on Clover's Trimer-Tag vaccine te
PR NewswireClover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive preliminary immunogenicity and safety data in the initial young adult cohort from its Phase I trial evaluating SCB-1019 – the company's bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate – which is based on Clover's Trimer-Tag vaccine tech
PR NewswireClover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company, today announced positive preliminary safety, efficacy and pharmacokinetics data in a Phase Ⅰ clinical trial evaluating SCB-219M, an innovative thrombopoietin receptor agonist (TPO-RA) mimetic bispecific Fc-fusion protein produced from CHO cells, for the treatment of cancer patients with chemotherapy-induced thrombocytopenia (CIT).
